Related Experiment Video
Updated: Jan 2, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Blockade of CCR5 in melanoma: An alternative immune checkpoint modulator
Julia Escandon Brehm1, Barbara Bedogni1
1Dr Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miami, FL, USA.
Abstract:
Melanoma is a deadly tumor, which in recent years has been successfully treated with immune checkpoint inhibitors as PD-1/PD-L1 and CTLA-4 inhibitors and targeted therapy as BRAF and MEK inhibitors. However, immunotherapy poses deleterious side effects and pursuit of new therapeutic targets is warranted. As knowledge of tumor immunology advances, such targets are being recognized. C-motif chemokine receptor-5 (CCR5) is a receptor found on immune cells whose effects impact the immune response both to induce inflammation and to activate suppressor cells causing an anti-inflammatory effect. CCR5 is well known as a target for HIV therapy where its blockade is efficient and safe, it is also known that its mutation CCR5delta32 is for the most part non-pathological to its carriers. In oncology, activation of the CCR5 receptor has been observed in high-stage disease and CCR5 blockade has been associated with an increased immune response. In this letter, we build up the rationale to utilize CCR5 as a therapeutic target for metastatic melanoma.
Insights
Targeting C-C motif chemokine receptor 5 (CCR5) offers a novel therapeutic strategy for metastatic melanoma. CCR5 blockade may enhance anti-tumor immune responses, addressing limitations of current immunotherapies.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Melanoma treatment has advanced with immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4) and targeted therapies (BRAF, MEK inhibitors).
- Current immunotherapies can cause severe side effects, necessitating the identification of novel therapeutic targets.
- C-C motif chemokine receptor 5 (CCR5) plays a dual role in immune responses, influencing inflammation and immune suppression.
Purpose of the Study:
- To establish the rationale for targeting CCR5 as a therapeutic strategy in metastatic melanoma.
- To explore the potential of CCR5 blockade in enhancing anti-tumor immunity.
Main Methods:
- Review of existing literature on CCR5 function in immunology and oncology.
- Analysis of CCR5's role in immune cell modulation and its implications for cancer.
- Evaluation of CCR5 blockade's safety and efficacy based on HIV therapy and genetic studies.
Main Results:
- CCR5 receptor activation is observed in advanced-stage melanoma.
- CCR5 blockade has been linked to augmented immune responses in preclinical or clinical settings.
- CCR5 is a known target in HIV therapy with a favorable safety profile; CCR5delta32 mutation is largely non-pathological.
Conclusions:
- CCR5 represents a promising therapeutic target for metastatic melanoma.
- Blocking CCR5 may overcome limitations associated with current immunotherapies.
- Further investigation into CCR5-targeted therapies for melanoma is warranted.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
07:41A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Related Concept Videos
01:27Tumor Immunotherapy
02:34Inhibition of Cdk Activity